Photo of Lee M. Nadler,  MD

Lee M. Nadler, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3331
Fax: (617) 632-3541


lee_nadler@dfci.harvard.edu

Lee M. Nadler, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Virginia and D.K. Ludwig Professor of Medicine, Medicine, Harvard Medical School
  • Chief, Medical Oncology, Brigham And Women's Hospital
  • Senior Vice President, Experimental Medicine, Dana-Farber Cancer Institute
  • Dean, Clinical and Translational Research, Harvard Catalyst - The Harvard Clinical and Translational Science Center

DF/HCC PROGRAM AFFILIATION

DF/HCC ASSOCIATIONS

  • Institutional Representative for DFCI, Membership Committee
  • Institutional Representative for DFCI, Executive Committee
  • Member, Center Scientific Council
  • Member, Clinical Science Coordinating Committee
  • Deputy Associate Director, Clinical Sciences, Executive Committee
  • Deputy Associate Director, Planning and Evaluation, Executive Committee

Publications

Powered by Harvard Catalyst
  • Barbon CM, Davies JK, Voskertchian A, Kelner RH, Brennan LL, Nadler LM, Guinan EC. Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells. Am J Transplant 2014; 14:305-18. PubMed
  • Davies JK, Barbon CM, Voskertchian A, Nadler LM, Guinan EC. Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant 2013; 21:2047-61. PubMed
  • Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 2011; 39:457-472.e3. PubMed
  • Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD, , . A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma 2011; 52:587-96. PubMed
  • Davies JK, Barbon CM, Voskertchian AR, Nadler LM, Guinan EC. Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. 2011. PubMed
  • Butler MO, Ansén S, Tanaka M, Imataki O, Berezovskaya A, Mooney MM, Metzler G, Milstein MI, Nadler LM, Hirano N. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol 2010; 22:863-73. PubMed
  • Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 2010; 70:3915-24. PubMed
  • Davies JK, Nadler LM, Guinan EC. Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med 2010; 1:1ra3. PubMed
  • Kondo E,Maecker B,Weihrauch MR,Wickenhauser C,Zeng W,Nadler LM,Schultze JL,von Bergwelt-Baildon MS. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res 2008; 14:6574-9. PubMed
  • Ansen S,Butler MO,Berezovskaya A,Murray AP,Stevenson K,Nadler LM,Hirano N. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res 2008; 14:6125-36. PubMed
  • Davies JK,Yuk D,Nadler LM,Guinan EC. Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation 2008; 86:854-64. PubMed
  • Davies JK,Gribben JG,Brennan LL,Yuk D,Nadler LM,Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 2008; 112:2232-41. PubMed
  • Haining WN,Davies J,Kanzler H,Drury L,Brenn T,Evans J,Angelosanto J,Rivoli S,Russell K,George S,Sims P,Neuberg D,Li X,Kutok J,Morgan J,Wen P,Demetri G,Coffman RL,Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res 2008; 14:5626-34. PubMed
  • Haining WN, Ebert BL, Subrmanian A, Wherry EJ, Eichbaum Q, Evans JW, Mak R, Rivoli S, Pretz J, Angelosanto J, Smutko JS, Walker BD, Kaech SM, Ahmed R, Nadler LM, Golub TR. Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells. J Immunol 2008; 181:1859-68. PubMed
  • Haining WN,Angelosanto J,Brosnahan K,Ross K,Hahn C,Russell K,Drury L,Norton S,Nadler L,Stegmaier K. High-throughput gene expression profiling of memory differentiation in primary human T cells. BMC Immunol 2008; 9:44. PubMed
  • Nadler LM, Roberts WC. Lee Marshall Nadler, MD: a conversation with the editor. Proc (Bayl Univ Med Cent) 2007; 20:381-9. PubMed
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13:1057-65. PubMed
  • Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS. Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up. J Clin Oncol 2007; 25:2554-9. PubMed
  • Butler MO, Lee JS, Ans. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell. Clin Cancer Res 2007; 13:1857-1867. PubMed
  • Hirano N, Butler M, Xia Z, Berezovskaya A, Murray AP, Ansen S, Kojima S, Nadler LM. Identification of an immunogenic CD8+ T cell epitope derived from {gamma}-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 2006; 108:2662-8. PubMed
  • Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ans. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 2006; 12:2967-75. PubMed
  • Veiga JP, Costa LF, Sallan SE, Nadler LM, Cardoso AA. Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol 2006; 34:610-21. PubMed
  • Zander T, Yunes JA, Cardoso AA, Nadler LM. Rapid, reliable and inexpensive quality assessment of biotinylated cRNA. Braz J Med Biol Res 2006; 39:589-93. PubMed
  • Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:2208-14. PubMed
Hide